StockData

Enovis vs Smith & Nephew

ENOV and SNN side by side, both in surgical, medical, and dental instruments and supplies. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How ENOV and SNN compare

Smith & Nephew grew revenue faster over the last twelve months (6.1% versus 4.9% for Enovis).

Enovis scores higher on the StockData Score (8 against 6 for Smith & Nephew), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricENOVSNN
Size and price
Market cap$1.6B–
Share price$27.22$30.51
Change, 1 year−9.2%−6.7%
Change, 5 years−81.3%−7.1%
Beta (5Y)0.080.11
Employees7,80218K
StockData Score
Total score8 (better)6
Valuation score4 (better)0
Growth score2 (better)1
Performance score01 (better)
Health score24 (better)
Dividend score00
Valuation
P/S0.7×–
P/B1.1×–
EV/EBITDA9.2×–
P/FCF24.7×–
FCF yield4.1%–
Fair value$81.07–
Margin of safety66.4%–
Growth
Revenue growth (TTM)4.9%6.1% (better)
Revenue growth, 5Y average14.9% (better)6.2%
EPS growth (TTM)–52.3%
EPS growth, 5Y average–6.9%
Profitability
Gross margin61.1%68.0% (better)
Operating margin−45.1%12.9% (better)
Net margin−48.0%–
FCF margin2.8%–
Return on equity−54.3%–
Return on invested capital−24.5%13.0% (better)
Financial health
Debt / equity0.870.10 (better)
Net debt / EBITDA4.12 (better)−0.31
Interest coverage−30.9×5.7× (better)
Current ratio1.982.14 (better)
Altman Z-score−0.24–
Piotroski F-score4–
Dividends and buybacks
Shareholder yield0.00%–
Ownership
Held by institutions122%4.2%
Held by insiders2.7%25.1%
Insider net buying, 12 months$842K–
Superinvestors holding1–
Short interest, % of float18.8%–

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.